NCT03384680 is a clinical trial in Lung Cancer, sponsored by Seong-Gyu Ko.

Who is sponsoring NCT03384680?

NCT03384680 is sponsored by Seong-Gyu Ko.

What condition does NCT03384680 study?

NCT03384680 studies Lung Cancer.

Is NCT03384680 still recruiting?

NCT03384680 is currently status unknown. Last updated 9 January 2018.

Last reviewed 2018-01-09 · How we verify

NCT03384680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Symptom Collection of Lung Cancer Patients

Status unknown Last updated 9 January 2018

What this trial tests

trial in Lung Cancer in 100 participants. Status unknown.

Timeline

16 September 2015

Primary endpoint
31 March 2018

31 May 2018

Quick facts

Lead sponsor	Seong-Gyu Ko
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	16 September 2015
Primary completion	31 March 2018
Estimated completion	31 May 2018
Sites	1 location across South Korea

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Seong-Gyu Ko — full company profile →

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted to collect the symptoms of lung cancer patients and to observe the relationship with proteomics.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pattern identification of lung cancer patients based on body constitution questionnaires (BCQ) and glycoproteomics for precision medicine.
Cho W, Kim JH, Jeong M, Kim MS, et al · · 2019 · cited 3× · PMID 31192960 · DOI 10.1097/md.0000000000016035

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Seong-Gyu Ko trials

Trials by the same sponsor.

NCT03384667 — Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer · Phase 2, PHASE3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03384680 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seong-Gyu Ko
Last refreshed: 9 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03384680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing